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Synopsis
Foreign-born individuals account for over 12% of the U.S. population,
according to the most recent census data. Since many vaccine-preventable
outbreaks in the U.S. have been correlated with disease importation, Congress
has mandated vaccinations for numerous immigrant populations. It is essential
for primary care physicians to be knowledgeable on the unique immunizationrelated needs of foreign-born individuals, to recognize some of the cultural and
linguistic challenges that immigrants have accessing healthcare, and remember
to use each medical encounter as an opportunity to provide necessary
vaccinations.

Introduction
2

At the time of the 2000 Census, foreign-born individuals accounted for
11.1% of the total U.S. population.1 By 2009, this percentage increased to 12%
totaling 36.7 million foreign-born individuals in the U.S.2 The U.S. foreign-born
population includes immigrants (legal permanent residents), humanitarian
migrants (e.g., refugees), temporary migrants (e.g., students), and unauthorized
migrants (undocumented individuals residing in the U.S.). Persons born abroad
to American parents or born in Puerto Rico or other U.S. Island Areas are not
considered foreign-born.1
Refugees constitute a special subset of the foreign-born population,
because of the sociopolitical factors leading to their migration. From 2000 to
2009, 618,090 refugees migrated to the U.S. from over 60 different countries. The
top 10 countries of origin were Cuba, the former Soviet Union, Somalia, former
Yugoslavia, Burma, Iraq, Iran, Liberia, Sudan, and Vietnam. Refugees in the U.S.
resettle in some regions more often than others, and the states with the largest
number of resettled refugees are Florida, California, Texas, New York, and
Minnesota.3
There is substantial evidence that many of the vaccine-preventable
outbreaks in the U.S. have been directly related to disease importation. In 2008,
close to 90% of the measles cases in the US were either acquired overseas or
imported cases, leading to 7 outbreaks and 135 infected persons.4 Even though
rubella disease is less severe than measles, congenital rubella syndrome can be
devastating and life-threatening. Fortunately, only two cases were reported in
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the U.S. in 2009.5 However, in one of the two cases, the individual was travelling
throughout her first trimester in India and China. For these reasons, Congress has
mandated vaccinations for immigrant populations in the US to decrease the
public health burden from imported vaccine-preventable diseases.
As a whole, foreign-born individuals have unique immunization-related
needs that can be influenced by country of origin, age of arrival to the U.S., and
circumstances surrounding their migration (e.g., refugees/asylees, adoptees).
Primary care physicians must be aware of these needs and be comfortable
providing the appropriate services to this population.

Start with the basics
In the primary care setting, foreign-born patients may present with
complicated medical and social histories, and it is important to keep in mind the
standard age-appropriate preventive care recommendations that apply to all
patients. Compared to their U.S. cohorts, foreign-born individuals may have
more difficulty accessing healthcare due to cultural and linguistic barriers.6,7
Foreign-born patients may be more likely to access healthcare for acute care
rather than for health maintenance, so sick visits should be viewed as an
opportunity to provide these important services, including vaccination. Many of
these patients will not return for a separate health maintenance visit, even if the
recommendation is made. In many developing countries, the concept of a
health maintenance visit is largely unknown, so the idea of returning to simply
4

discuss wellness issues may be viewed with skepticism, even if patients outwardly
voice agreement with the follow-up plan. Vaccination should not be delayed
due to mild respiratory tract infections or other acute illness, although
vaccination should be deferred for moderate or severe illness.8
Assessing Risk: Important Vaccine-Preventable Diseases for Foreign-Born
Populations
Knowing a patient’s country of origin can help to assess the patient’s level
of risk for certain preventable diseases. Unfortunately, for the sake of examining
the incidence of disease in these populations, immigrants are usually grouped
together as a single unit, even though the incidence and prevalence of
diseases differs among particular subgroups. In addition, it is also important for
the primary care physician to have a general understanding of the cultural
norms in these individuals, to better assess an individual’s risk for disease (i.e. the
risk of sexually-transmitted infections in populations with a high prevalence of
sexual abuse).
Despite near total eradication of numerous vaccine-preventable diseases
in the U.S., the
rest of the world has not been as fortunate. In 2002, WHO (World Health
Organization)
estimated that 14% (1.4 million deaths) of the total global mortality in children
under the age of
5 years old was due to disease that could have been prevented with routine
vaccination. The
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distribution of these deaths is seen in Figure 1.9
In the following sections we will focus specifically on tuberculosis, viral hepatitis,
and human papillomavirus. These conditions were selected for special emphasis
due to the greater burden of disease caused by these infections among
immigrant populations.
Infectious Disease Burden: TUBERCULOSIS
Tuberculosis (TB) is very common in much of the world, with the continent
of Africa having the largest number of high-prevalence nations. Continents with
lowest rates of tuberculosis include North America, Europe, and Australia.
According to the World Health Organization, the country with the highest
incidence for the combined years of 2007-2008 was Swaziland in southern
Africa, with an incidence of 510 per 100,000 population (compared to 2 per
100,000 in the U.S.).10
Although immunization against TB is not commonly performed (and not
routinely recommended) in the U.S.,11 there are many parts of the world where
for years children have been routinely given the BCG (Bacille Calmette-Guérin)
vaccine to prevent TB. While the vaccine has not been shown to make a large
epidemiologic impact on TB infection per se, it seems to confer some protection
against serious TB disease among children, and may also protect against the
development of leprosy.12 Prior vaccination with BCG can sometimes result in
false positive results for the standard tuberculin skin test (TST).13 Since many
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foreign-born individuals come from areas with endemic TB, further testing is
necessary to identify these high-risk individuals.
Two newer blood tests serve as alternatives to the TST and are unaffected
by prior BCG vaccination: the ELISA-based QuantiFERON-TB Gold, which
measures interferon gamma concentration in supernatant, and the enzymelinked immunospot (ELISpot; T-SPOT TB), which enumerates interferon-gammasecreting T cells. Both tests have better specificity than the TST, although the
immunospot test appears to have higher sensitivity for detecting latent
tuberculosis infection.13 Despite decreases in active TB cases for US-born
individuals, the numbers of active TB cases among foreign-born individuals in the
US is still relatively elevated and have remained stable over the years (Figures
2,3). Identification and treatment of these individuals is necessary to decrease
the burden of tuberculosis disease. Unfortunately, simple, inexpensive point-ofcare tests with this level of sensitivity and specificity are still not available.14
Infectious Disease Burden: HEPATITIS A
Since the introduction of hepatitis A vaccination in 1995, cases of HAV in
the U.S. have dropped 84%.17 However, hepatitis A remains endemic in many
parts of the world. High prevalence regions include sub-Saharan Africa and
parts of south Asia, where it is estimated that ≥90% of the population have
serologic evidence of infection by age 10. Intermediate prevalence occurs in
Latin America, northern Africa, and the Middle East (≥50% with evidence of
7

infection by age 15).18 Chronic hepatitis A has not been reported, although 1020% of symptomatic patients experience a prolonged or relapsing course.19 For
all patients, but particularly those who have recently traveled from high-risk
regions, hepatitis A should be considered in the setting of symptoms such as
abdominal pain, fatigue, nausea, anorexia, urticaria and jaundice. It is
important to note, however, that infected children may be asymptomatic; only
about 30% of infected children exhibit symptoms (often non-specific flu-like
symptoms), and viral shedding may continue in their stools for 6 months.19
Infectious Disease Burden: HEPATITIS B
Hepatitis B is endemic in many regions of the world as well, including
much of Eastern Europe, Asia, Africa, the Middle East, and the Pacific Islands
(see Figure 4). Chronic hepatitis B infection can result in liver failure, cirrhosis, and
hepatocellular carcinoma. Only 0.3-0.5% of the U.S. population is chronically
infected with hepatitis B, but among foreign-born individuals, prevalence is 1.02.6%.16
People who come from countries with ≥2% hepatitis B prevalence are at
greatest risk for both active and chronic hepatitis B infection. These individuals
should be screened via Hepatitis B surface antigen testing (HBsAg) and
immunized if they are not infected (unless there is documentation that there has
been prior completion of the immunization series). For foreign-born persons from
high-risk countries, HBsAg testing is warranted even when there is a documented
8

history of immunization, because it is possible that infection could have occurred
prior to immunization. In addition, testing is also recommended for U.S.-born
persons who were not vaccinated as infants and whose parents were born in
regions with ≥8% HBV endemicity (e.g., Peru, northern Brazil, Greenland, subSaharan Africa, Saudi Arabia, and much of Asia and the Pacific Islands).16 For
individuals with unknown hepatitis B immunization history, it is reasonable to
consider testing for Hepatitis B surface antibody (HBsAb) before deciding to
immunize; however, if the cost of serologic testing exceeds the cost of
immunization, it might be more cost effective merely to vaccinate.
Infectious Disease Burden: HUMAN PAPILLOMAVIRUS
There is clear evidence in the medical literature to support the direct
relationship that human papilloma virus (HPV) has on the development of
cancer, including cervical, vulvar, anal, penile and oropharyngeal. HPV has
been recognized as the cause of essentially all cervical cancers.20-22 Even
though the number of cervical cancer cases in the US are very low, cervical
cancer affects many women worldwide.23,24 HPV vaccines that are available in
the US and other countries have been shown to prevent the transmission of the
high-risk HPV subtypes that pose the greatest risk to the development of cervical
cancer.24 For many foreign-born individuals, they are likely to be behind in
cervical cancer screening. Administration of the HPV vaccine to this population
at the earliest visit to the healthcare provider is essential in lowering the
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incidence of cervical cancer. It is important to remember, however, that HPV
immunization does not prevent infection of all oncogenic HPV subtypes (only 16
and 18), nor does it treat infections that have already occurred prior to
immunization. Therefore, Pap testing is still an essential component in the
prevention of cervical cancer, regardless of HPV immunization status.
Travel Medicine
Foreign-born individuals may travel back and forth between the U.S. and
their country of origin, or they may have frequent contact with other people
who are from that part of the world. Consequently, it might be advisable to
consider immunization against illnesses that are common in the country of origin,
especially if the patient anticipates traveling there in the near future. The CDC
has a comprehensive travel website (http://wwwnc.cdc.gov/travel/) that can
serve as an important resource. More information about travel-related
immunizations can be found elsewhere in this issue.
Special Considerations for Refugee Populations
According to the United Nations Convention Relating to the Status of
Refugees (Article 1A: 1951), a refugee is “someone who, owing to a wellfounded fear of being persecuted for reasons of race, religion, nationality,
membership of a particular social group, or political opinion, is outside the
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country of his nationality, and is unable to or, owing to such fear, is unwilling to
avail himself of the protection of that country.”25
Approximately 80,000 refugees arrive annually into the U.S., with over 2
million arrivals since 1980.26 Refugees bring a unique set of medical issues and
conditions that must be addressed by the treating healthcare provider. Prior to
arrival in the U.S., all refugees undergo an overseas medical examination with
the purpose of identifying any diseases (i.e. active tuberculosis, leprosy) that
would preclude travel to the U.S. Depending on the country of origin,
vaccinations may also be provided at the time of this exam.
According to the Immigration and Nationality Act (Section 212), any
individual seeking admission to the U.S. as either an incoming immigrant, or as
an immigrant seeking an adjustment of status for permanent U.S. residence
(green card), is ineligible for admission to the U.S. if they are unable to present
the appropriate documentation of having received vaccinations against
‘‘vaccine- preventable diseases, which shall include at least the following
diseases: Mumps, measles, rubella, polio, tetanus and diphtheria toxoids,
pertussis, Haemophilus influenzae type B, and hepatitis B, and any other
vaccinations against vaccine-preventable diseases recommended by the
Advisory Committee on Immunization Practices (ACIP).’’ Vaccinations given
overseas are considered acceptable if they have been given at the
appropriate intervals and age guidelines.
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All refugees are eligible for adjustment of status after they have lived in
the U.S. for 1 year. For this reason, vaccination is an essential piece in the
medical care of newly arrived refugees to the US. In addition, in order for
refugee children to attend school in the US, they must have either appropriate
documentation of vaccinations provided overseas, or have initiated the
vaccination series in the U.S. Due to the large number of vaccinations that are
required for both children and adults, healthcare providers need to be very
familiar with the CDC’s guidelines on vaccinations, including child, adolescent,
adult and catch-up schedules. As of December 14, 2009, the CDC has new
criteria that will be used to decide which vaccines will be required as part of the
immigration process. The criteria are as follows:
(1)
(2)

The vaccine must be an age- appropriate vaccine as recommended
by the ACIP for the general U.S. population, and
At least one of the following:
a. The vaccine must protect against a disease that has the
potential to cause an outbreak.
b. The vaccine must protect against a disease that has been
eliminated in the United States or is in the process for elimination in
the United States.

Any changes made by the CDC will be reflected in the CDC’s Technical
Instructions for Panel Physicians for Vaccinations.
(http://www.cdc.gov/immigrantrefugeehealth) The current requirements for
routine vaccination during the immigration process are seen in Table 1 below.
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International Adoptees and Others Receiving Vaccination Outside the United
States
Evidence of immunization prior to coming to the U.S. must be proven by
written documentation, with the exception of influenza and pneumococcal
polysaccharide vaccine, for which verbal history is acceptable. Adequate
protection is most likely if the vaccination history closely matches the U.S.
immunization schedule with regard to age of administration and immunization
interval. Even with documented immunizations, however, it is possible that
serologic testing may reveal inadequate protection. Repeating of immunizations
according to the catch-up schedule is an appropriate option to ensure
protection.8
Vaccination/revaccination is recommended for MMR and polio. In
addition, age-appropriate vaccination/revaccination is recommended for Hib,
HAV, HBV (along with HBsAg testing), varicella (if lacking evidence of immunity),
pneumococcal conjugate, rotavirus, HPV, and zoster. Alternatively, MMR,
poliovirus and HAV immunity can be determined through serologic testing
before deciding to administer these vaccines.8
Revaccination is also recommended for DTaP, but adverse local reactions
are more common after the 4th or 5th dose. Therefore, if a severe local reaction
occurs, IgG titers for tetanus and diphtheria toxins should be obtained before
deciding to proceed with additional DTaP administrations (while serologic tests
13

exist for tetanus/diphtheria, there are no currently available serologic tests to
confirm adequate immunity against pertussis). For foreign-born children with 3 or
more documented doses of DTaP prior to coming to the U.S., it is also
appropriate to do tetanus/diphtheria serologic testing at initial presentation or 1
month after a booster dose. If adequate immunity is demonstrated, only
standard age-appropriate immunizations would be necessary after that point.
For older persons, Tdap should be administered as appropriate based on
standard guidelines.8

Summary
Despite the great progress that has been made in the U.S. in the last
century with vaccine-preventable diseases, significant morbidity and mortality is
seen throughout the world in individuals who have not been vaccinated. As the
foreign-born population in the U.S. continues to rise, primary care physicians
must feel comfortable treating these individuals in a culturally and linguisticallyappropriate manner.
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Figure 1: Distribution of estimated annual deaths from vaccine-preventable
diseases, 2002.9
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FIGURE 2: Number and rate* of tuberculosis (TB) cases among U.S.-born and foreignborn persons, by year --- United States, 1993—2010.15

Figure 3: Number of TB cases reported among U.S. born and foreign-born
individuals (1999-2009).5
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Figure 4: Geographic distribution of chronic hepatitis B virus (HBV) infection – worldwide,
2006.16
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Table 1: Requirements for routine vaccination of immigrants examined overseas who are not
fully vaccinated or lack documentation.27
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